Neonatal autoimmune diseases: A critical review

Journal of Autoimmunity

Volumn 38, Issue 2-3, 2012, Pages

  Chang, Christopher ^a  

^a NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

Author keywords

Amyloidosis; Anti phospholipid syndrome; Arthropathy; CINCA; Congenital; Cryopyrin; Familial cold autoinflammatory syndrome; Heart block; La; Microchimerism; Molecular mimicry; Muckle Wells syndrome; Neonatal autoimmune disease; Neonatal lupus; Neonatal onset multisystem inflammatory disease; NOMID; Ro

Indexed keywords

C REACTIVE PROTEIN; CANAKINUMAB; CRYOPYRIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 18; INTERLEUKIN 1BETA; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT;

ANTIGEN ANTIBODY REACTION; ANTIPHOSPHOLIPID SYNDROME; APOPTOSIS; ARTHRALGIA; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BACTERIAL ARTHRITIS; BEHCET DISEASE; BLAU SYNDROME; BURNING SENSATION; CEREBROSPINAL FLUID ANALYSIS; CINCA SYNDROME; DERMATOMYOSITIS; DROWSINESS; ERYTHROCYTE SEDIMENTATION RATE; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; FAMILIAL MEDITERRANEAN FEVER; FETUS CELL; FEVER; GENETIC ANALYSIS; GENETIC ASSOCIATION; GESTATIONAL AGE; GRAVES DISEASE; HEADACHE; HEARING LOSS; HEART BLOCK; HEMATOPOIETIC STEM CELL; HEREDITARY PERIODIC FEVER; HOMEOSTASIS; HUMAN; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; IMMUNE SYSTEM; INJECTION SITE REACTION; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FUNCTION TEST; LEUKOCYTOSIS; LUPUS VULGARIS; MICROCHIMERISM; MUCKLE WELLS SYNDROME; MUCOCUTANEOUS LYMPH NODE SYNDROME; NEUTROPHIL COUNT; NEWBORN DISEASE; NONHUMAN; ORGANOGENESIS; POLYMYOSITIS; PRIMARY IMMUNE RESPONSE; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; RASH; REVIEW; SCHNITZLER SYNDROME; SCLERODERMA; SEX DIFFERENCE; SKIN BIOPSY; SWEATING; T LYMPHOCYTE; THYMUS; THYROID DISEASE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; UNSPECIFIED SIDE EFFECT; URINALYSIS; URTICARIA;

AUTOIMMUNE DISEASES; FEMALE; HUMANS; IMMUNE SYSTEM; INFANT, NEWBORN; INFLAMMATION; MALE; SEX FACTORS;

EID: 84862804191     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2011.11.018     Document Type: Review

References (126)

1. Tavian M., Biasch K., Sinka L., Vallet J., Peault B. Embryonic origin of human hematopoiesis. Int J Dev Biol 2010, 54:1061-1065.
2. Kawai T., Malech H.L. WHIM syndrome: congenital immune deficiency disease. Curr Opin Hematol 2009, 16:20-26.
3. Haynes B.F., Hale L.P. The human thymus. A chimeric organ comprised of central and peripheral lymphoid components. Immunol Res 1998, 18:61-78.
4. Cupedo T. Human lymph node development: an inflammatory interaction. Immunol Lett 2011, 138:4-6.
5. Aoki H, Inamura N, Kawazu Y, Nakayama M, Kayatani F. Fetal echocardiographic assessment of endocardial fibroelastosis in maternal anti-SSA antibody-associated complete heart block. Circ J;75:1215-1221.
6. Moon-Grady AJ, Moore P, Azakie A. Ross-Konno and endocardial fibroelastosis resection after hybrid stage I palliation in infancy: successful staged left-ventricular rehabilitation and conversion to biventricular circulation after fetal diagnosis of aortic stenosis. Pediatr Cardiol;32:211-214.
7. Borlawsky T.B., Li J., Shagina L., Crowson M.G., Liu Y., Friedman C., et al. Evaluation of an ontology-anchored natural language-based approach for asserting multi-scale biomolecular networks for systems medicine. AMIA Summits Transl Sci Proc 2010, 6-10.
8. De Wit D., Olislagers V., Goriely S., Vermeulen F., Wagner H., Goldman M., et al. Blood plasmacytoid dendritic cell responses to CpG oligodeoxynucleotides are impaired in human newborns. Blood 2004, 103:1030-1032.
9. Davies N.P., Buggins A.G., Snijders R.J., Jenkins E., Layton D.M., Nicolaides K.H. Blood leucocyte count in the human fetus. Arch Dis Child 1992, 67:399-403.
10. Omar S.A., Salhadar A., Wooliever D.E., Alsgaard P.K. Late-onset neutropenia in very low birth weight infants. Pediatrics 2000, 106. E55.
11. Carr R. Neutrophil production and function in newborn infants. Br J Haematol 2000, 110:18-28.
12. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev Immunol 2007, 7:379-390.
13. Guilmot A., Hermann E., Braud V.M., Carlier Y., Truyens C. Natural killer cell responses to infections in early life. J Innate Immun 2011, 3:280-288.
14. Satwani P., Morris E., van de Ven C., Cairo M.S. Dysregulation of expression of immunoregulatory and cytokine genes and its association with the immaturity in neonatal phagocytic and cellular immunity. Biol Neonate 2005, 88:214-227.
15. Forst L, Friedman L, Chukwu A. Reliability of the AMA guides to the evaluation of permanent impairment. J Occup Environ Med;52:1201-1203.
16. Friedman A, Shaldubina A, Flaumenhaft Y, Weizman A, Yadid G. Monitoring of circadian rhythms of heart rate, locomotor activity, and temperature for diagnosis and evaluation of response to treatment in an animal model of depression. J Mol Neurosci;43:303-308.
17. Walker J.C., Smolders M.A., Gemen E.F., Antonius T.A., Leuvenink J., de Vries E. Development of lymphocyte subpopulations in preterm infants. Scand J Immunol 2011, 73:53-58.
18. Pan-Hammarstrom Q., Zhao Y., Hammarstrom L. Class switch recombination: a comparison between mouse and human. Adv Immunol 2007, 93:1-61.
19. Zemlin M., Hoersch G., Zemlin C., Pohl-Schickinger A., Hummel M., Berek C., et al. The postnatal maturation of the immunoglobulin heavy chain IgG repertoire in human preterm neonates is slower than in term neonates. J Immunol 2007, 178:1180-1188.
20. Moore T. Review: parent-offspring conflict and the control of placental function. Placenta 2011.
21. Kile R., Rusk H. A case of cold urticaria with an unusual family history. J Am Med Assoc 1950, 114:1067-1068.
22. Muckle T.J., Wellsm Urticaria, deafness, and amyloidosis: a new heredo-familial syndrome. Q J Med 1962, 31:235-248.
23. Lorber J. Syndrome for diagnosis: dwarfing, persistently open fontanelle; recurrent meningitis; recurrent subdural effusions with temporary alternate-sided hemiplegia; high-tone deafness; visual defect with pseudopapilloedema; slowing intellectual development; recurrent acute polyarthritis; erythema marginatum, splenomegaly and iron-resistant hypochromic anaemia. Proc R Soc Med 1973, 66:1070-1071.
24. Bauernfeind F., Ablasser A., Bartok E., Kim S., Schmid-Burgk J., Cavlar T., et al. Inflammasomes: current understanding and open questions. Cell Mol Life Sci 2011, 68:765-783.
25. Thomas P.G., Dash P., Aldridge J.R., Ellebedy A.H., Reynolds C., Funk A.J., et al. The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. Immunity 2009, 30:566-575.
26. Duncan J.A., Gao X., Huang M.T., O'Connor B.P., Thomas C.E., Willingham S.B., et al. Neisseria gonorrhoeae activates the proteinase cathepsin B to mediate the signaling activities of the NLRP3 and ASC-containing inflammasome. J Immunol 2009, 182:6460-6469.
27. Kanneganti T.D., Ozoren N., Body-Malapel M., Amer A., Park J.H., Franchi L., et al. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 2006, 440:233-236.
28. Kanneganti T.D., Body-Malapel M., Amer A., Park J.H., Whitfield J., Franchi L., et al. Critical role for Cryopyrin/Nalp3 in activation of caspase-1 in response to viral infection and double-stranded RNA. J Biol Chem 2006, 281:36560-36568.
29. Martinon F., Agostini L., Meylan E., Tschopp J. Identification of bacterial muramyl dipeptide as activator of the NALP3/cryopyrin inflammasome. Curr Biol 2004, 14:1929-1934.
30. Martinon F., Petrilli V., Mayor A., Tardivel A., Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237-241.
31. Mariathasan S., Weiss D.S., Newton K., McBride J., O'Rourke K., Roose-Girma M., et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006, 440:228-232.
32. Feldmeyer L., Keller M., Niklaus G., Hohl D., Werner S., Beer H.D. The inflammasome mediates UVB-induced activation and secretion of interleukin-1beta by keratinocytes. Curr Biol 2007, 17:1140-1145.
33. Petrilli V., Papin S., Dostert C., Mayor A., Martinon F., Tschopp J. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ 2007, 14:1583-1589.
34. Neven B., Prieur A.M., Quartier dit Maire P. Cryopyrinopathies: update on pathogenesis and treatment. Nat Clin Pract Rheumatol 2008, 4:481-489.
35. Hawkins P.N., Lachmann H.J., Aganna E., McDermott M.F. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004, 50:607-612.
36. Montealegre Sanchez G.A., Hashkes P.J. Neurological manifestations of the Mendelian-inherited autoinflammatory syndromes. Dev Med Child Neurol 2009, 51:420-428.
37. Lachmann H.J., Quartier P., So A., Hawkins P.N. The emerging role of interleukin-1beta in autoinflammatory diseases. Arthritis Rheum 2011, 63:314-324.
38. Hoffman H.M., Rosengren S., Boyle D.L., Cho J.Y., Nayar J., Mueller J.L., et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004, 364:1779-1785.
39. Ross J.B., Finlayson L.A., Klotz P.J., Langley R.G., Gaudet R., Thompson K., et al. Use of anakinra (Kineret) in the treatment of familial cold autoinflammatory syndrome with a 16-month follow-up. J Cutan Med Surg 2008, 12:8-16.
40. Mirault T., Launay D., Cuisset L., Hachulla E., Lambert M., Queyrel V., et al. Recovery from deafness in a patient with Muckle-Wells syndrome treated with anakinra. Arthritis Rheum 2006, 54:1697-1700.
41. Hawkins P.N., Lachmann H.J., McDermott M.F. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 2003, 348:2583-2584.
42. Kuemmerle-Deschner J.B., Tyrrell P.N., Koetter I., Wittkowski H., Bialkowski A., Tzaribachev N., et al. Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome. Arthritis Rheum 2011, 63:840-849.
43. Leslie K.S., Lachmann H.J., Bruning E., McGrath J.A., Bybee A., Gallimore J.R., et al. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol 2006, 142:1591-1597.
44. Goldbach-Mansky R., Dailey N.J., Canna S.W., Gelabert A., Jones J., Rubin B.I., et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006, 355:581-592.
45. Neven B., Marvillet I., Terrada C., Ferster A., Boddaert N., Couloignier V., et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum 2010, 62:258-267.
46. Goldbach-Mansky R. Current status of understanding the pathogenesis and management of patients with NOMID/CINCA. Curr Rheumatol Rep 2011, 13:123-131.
47. Goldbach-Mansky R., Shroff S.D., Wilson M., Snyder C., Plehn S., Barham B., et al. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum 2008, 58:2432-2442.
48. Hoffman H.M., Throne M.L., Amar N.J., Sebai M., Kivitz A.J., Kavanaugh A., et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008, 58:2443-2452.
49. Lachmann H.J., Kone-Paut I., Kuemmerle-Deschner J.B., Leslie K.S., Hachulla E., Quartier P., et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009, 360:2416-2425.
50. Brucato A., Cimaz R., Stramba-Badiale M. Neonatal lupus. Clin Rev Allergy Immunol 2002, 23:279-299.
51. Alspaugh M., Maddison P. Resolution of the identity of certain antigen-antibody systems in systemic lupus erythematosus and Sjogren's syndrome: an interlaboratory collaboration. Arthritis Rheum 1979, 22:796-798.
52. Mattioli M., Reichlin M. Heterogeneity of RNA protein antigens reactive with sera of patients with systemic lupus erythematosus. Description of a cytoplasmic nonribosomal antigen. Arthritis Rheum 1974, 17:421-429.
53. Alspaugh M.A., Tan E.M. Antibodies to cellular antigens in Sjogren's syndrome. J Clin Invest 1975, 55:1067-1073.
54. Alspaugh M.A., Talal N., Tan E.M. Differentiation and characterization of autoantibodies and their antigens in Sjogren's syndrome. Arthritis Rheum 1976, 19:216-222.
55. Franceschini F., Cavazzana I. Anti-Ro/SSA and La/SSB antibodies. Autoimmunity 2005, 38:55-63.
56. O'Brien C.A., Wolin S.L. A possible role for the 60-kD Ro autoantigen in a discard pathway for defective 5S rRNA precursors. Genes Dev 1994, 8:2891-2903.
57. Bachmann M., Pfeifer K., Schroder H.C., Muller W.E. Characterization of the autoantigen La as a nucleic acid-dependent ATPase/dATPase with melting properties. Cell 1990, 60:85-93.
58. Buyon J.P., Ben-Chetrit E., Karp S., Roubey R.A., Pompeo L., Reeves W.H., et al. Acquired congenital heart block. Pattern of maternal antibody response to biochemically defined antigens of the SSA/Ro-SSB/La system in neonatal lupus. J Clin Invest 1989, 84:627-634.
59. Defendenti C., Atzeni F., Spina M.F., Grosso S., Cereda A., Guercilena G., et al. Clinical and laboratory aspects of Ro/SSA-52 autoantibodies. Autoimmun Rev 2011, 10:150-154.
60. Rekvig O.P., Putterman C., Casu C., Gao H.X., Ghirardello A., Mortensen E.S., et al. Autoantibodies in lupus: Culprits or passive bystanders?. Autoimmun Rev 2011.
61. Ambrosio P., Lermann R., Cordeiro A., Borges A., Nogueira I., Serrano F. Lupus and pregnancy-15 years of experience in a tertiary center. Clin Rev Allergy Immunol 2010, 38:77-81.
62. Loewenstein A, Ferencz JR, Lang Y, Yeshurun I, Pollack A, Siegal R et al. Toward earlier detection of choroidal neovascularization secondary to age-related macular degeneration: multicenter evaluation of a preferential hyperacuity perimeter designed as a home device. Retina;30:1058-1064.
63. Pisoni C.N., Brucato A., Ruffatti A., Espinosa G., Cervera R., Belmonte-Serrano M., et al. Failure of intravenous immunoglobulin to prevent congenital heart block: findings of a multicenter, prospective, observational study. Arthritis Rheum 2010, 62:1147-1152.
64. Agmon-Levin N., Mosca M., Petri M., Shoenfeld Y. Systemic lupus erythematosus one disease or many?. Autoimmun Rev 2011.
65. Costenbader K.H., Gay S., Riquelme M.E., Iaccarino L., Doria A. Genes, epigenetic regulation and environmental factors: which is the most relevant in developing autoimmune diseases?. Autoimmun Rev 2011.
66. Lu Q., Renaudineau Y., Cha S., Ilei G., Brooks W.H., Selmi C., et al. Epigenetics in autoimmune disorders: highlights of the 10th Sjogren's syndrome symposium. Autoimmun Rev 2010, 9:627-630.
67. Brooks W.H., Le Dantec C., Pers J.O., Youinou P., Renaudineau Y. Epigenetics and autoimmunity. J Autoimmun 2010, 34:J207-J219.
68. Miranda M.E., Tseng C.E., Rashbaum W., Ochs R.L., Casiano C.A., Di Donato F., et al. Accessibility of SSA/Ro and SSB/La antigens to maternal autoantibodies in apoptotic human fetal cardiac myocytes. J Immunol 1998, 161:5061-5069.
69. Tran H.B., Macardle P.J., Hiscock J., Cavill D., Bradley J., Buyon J.P., et al. Anti-La/SSB antibodies transported across the placenta bind apoptotic cells in fetal organs targeted in neonatal lupus. Arthritis Rheum 2002, 46:1572-1579.
70. Boutjdir M., Chen L., Zhang Z.H., Tseng C.E., DiDonato F., Rashbaum W., et al. Arrhythmogenicity of IgG and anti-52-kD SSA/Ro affinity-purified antibodies from mothers of children with congenital heart block. Circ Res 1997, 80:354-362.
71. Karnabi E., Qu Y., Wadgaonkar R., Mancarella S., Yue Y., Chahine M., et al. Congenital heart block: identification of autoantibody binding site on the extracellular loop (domain I, S5-S6) of alpha(1D) L-type Ca channel. J Autoimmun 2010, 34:80-86.
72. Adams Waldorf K.M., Nelson J.L. Autoimmune disease during pregnancy and the microchimerism legacy of pregnancy. Immunol Invest 2008, 37:631-644.
73. Stevens A.M., Hermes H.M., Rutledge J.C., Buyon J.P., Nelson J.L. Myocardial-tissue-specific phenotype of maternal microchimerism in neonatal lupus congenital heart block. Lancet 2003, 362:1617-1623.
74. von der Thusen JH, Hansell DM, Tominaga M, Veys PA, Ashworth MT, Owens CM et al. Pleuroparenchymal fibroelastosis in patients with pulmonary disease secondary to bone marrow transplantation. Mod Pathol;24:1633-1639.
75. Munoz-Suano A., Kallikourdis M., Sarris M., Betz A.G. Regulatory T cells protect from autoimmune arthritis during pregnancy. J Autoimmun 2011.
76. Wahren-Herlenius M., Sonesson S.E. Specificity and effector mechanisms of autoantibodies in congenital heart block. Curr Opin Immunol 2006, 18:690-696.
77. Siren M.K., Julkunen H., Kaaja R., Ekblad H., Koskimies S. Role of HLA in congenital heart block: susceptibility alleles in children. Lupus 1999, 8:60-67.
78. Hill S.C., Namde M., Dwyer A., Poznanski A., Canna S., Goldbach-Mansky R. Arthropathy of neonatal onset multisystem inflammatory disease (NOMID/CINCA). Pediatr Radiol 2007, 37:145-152.
79. Brucato A, Cimaz R, Caporali R, Ramoni V, Buyon J. Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies. Clin Rev Allergy Immunol;40:27-41.
80. Buyon J.P., Hiebert R., Copel J., Craft J., Friedman D., Katholi M., et al. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol 1998, 31:1658-1666.
81. Shinohara K., Miyagawa S., Fujita T., Aono T., Kidoguchi K. Neonatal lupus erythematosus: results of maternal corticosteroid therapy. Obstet Gynecol 1999, 93:952-957.
82. Izmirly P.M., Llanos C., Lee L.A., Askanase A., Kim M.Y., Buyon J.P. Cutaneous manifestations of neonatal lupus and risk of subsequent congenital heart block. Arthritis Rheum 2010, 62:1153-1157.
83. Piciucchi S, Tomassetti S, Casoni G, Sverzellati N, Carloni A, Dubini A et al. High resolution CT and histological findings in idiopathic pleuroparenchymal fibroelastosis: features and differential diagnosis. Respir Res;12:111.
84. Friedman D.M., Kim M.Y., Copel J.A., Davis C., Phoon C.K., Glickstein J.S., et al. Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR Interval and Dexamethasone Evaluation (PRIDE) prospective study. Circulation 2008, 117:485-493.
85. Askanase A.D., Friedman D.M., Copel J., Dische M.R., Dubin A., Starc T.J., et al. Spectrum and progression of conduction abnormalities in infants born to mothers with anti-SSA/Ro-SSB/La antibodies. Lupus 2002, 11:145-151.
86. Breur J.M., Visser G.H., Kruize A.A., Stoutenbeek P., Meijboom E.J. Treatment of fetal heart block with maternal steroid therapy: case report and review of the literature. Ultrasound Obstet Gynecol 2004, 24:467-472.
87. Guettrot-Imbert G., Cohen L., Fermont L., Villain E., Frances C., Thiebaugeorges O., et al. A new presentation of neonatal lupus: 5 cases of isolated mild endocardial fibroelastosis associated with maternal Anti-SSA/Ro and Anti-SSB/La antibodies. J Rheumatol 2011, 38:378-386.
88. Jaeggi E.T., Hamilton R.M., Silverman E.D., Zamora S.A., Hornberger L.K. Outcome of children with fetal, neonatal or childhood diagnosis of isolated congenital atrioventricular block. A single institution's experience of 30 years. J Am Coll Cardiol 2002, 39:130-137.
89. Kobayashi R., Mii S., Nakano T., Harada H., Eto H. Neonatal lupus erythematosus in Japan: a review of the literature. Autoimmun Rev 2009, 8:462-466.
90. Neiman A.R., Lee L.A., Weston W.L., Buyon J.P. Cutaneous manifestations of neonatal lupus without heart block: characteristics of mothers and children enrolled in a national registry. J Pediatr 2000, 137:674-680.
91. Laxer R.M., Roberts E.A., Gross K.R., Britton J.R., Cutz E., Dimmick J., et al. Liver disease in neonatal lupus erythematosus. J Pediatr 1990, 116:238-242.
92. Lee L.A., Reichlin M., Ruyle S.Z., Weston W.L. Neonatal lupus liver disease. Lupus 1993, 2:333-338.
93. Cimaz R., Spence D.L., Hornberger L., Silverman E.D. Incidence and spectrum of neonatal lupus erythematosus: a prospective study of infants born to mothers with anti-Ro autoantibodies. J Pediatr 2003, 142:678-683.
94. Watson R., Kang J.E., May M., Hudak M., Kickler T., Provost T.T. Thrombocytopenia in the neonatal lupus syndrome. Arch Dermatol 1988, 124:560-563.
95. Tincani A., Nuzzo M., Motta M., Zatti S., Lojacono A., Faden D. Autoimmunity and pregnancy: autoantibodies and pregnancy in rheumatic diseases. Ann N Y Acad Sci 2006, 1069:346-352.
96. Lockshin M.D., Bonfa E., Elkon K., Druzin M.L. Neonatal lupus risk to newborns of mothers with systemic lupus erythematosus. Arthritis Rheum 1988, 31:697-701.
97. Wolach B., Choc L., Pomeranz A., Ben Ari Y., Douer D., Metzker A. Aplastic anemia in neonatal lupus erythematosus. Am J Dis Child 1993, 147:941-944.
98. Soares Rolim A.M., Castro M., Santiago M.B. Neonatal antiphospholipid syndrome. Lupus 2006, 15:301-303.
99. Galarza-Maldonado C., Kourilovitch M.R., Perez-Fernandez O.M., Gaybor M., Cordero C., Cabrera S., et al. Obstetric antiphospholipid syndrome. Autoimmun Rev 2011.
100. Tincani A., Rebaioli C.B., Andreoli L., Lojacono A., Motta M. Neonatal effects of maternal antiphospholipid syndrome. Curr Rheumatol Rep 2009, 11:70-76.
101. Chou A.K., Hsieh S.C., Su Y.N., Jeng S.F., Chen C.Y., Chou H.C., et al. Neonatal and pregnancy outcome in primary antiphospholipid syndrome: a 10-year experience in one medical center. Pediatr Neonatol 2009, 50:143-146.
102. Boffa M.C., Lachassinne E. Infant perinatal thrombosis and antiphospholipid antibodies: a review. Lupus 2007, 16:634-641.
103. Cohen S.B., Goldenberg M., Rabinovici J., Lidor A.L., Dulitzky M., Gilburd B., et al. Anti-cardiolipin antibodies in fetal blood and amniotic fluid derived from patients with the anti-phospholipid syndrome. Hum Reprod 2000, 15:1170-1172.
104. Alessandri C., Conti F., Pendolino M., Mancini R., Valesini G. New autoantigens in the antiphospholipid syndrome. Autoimmun Rev 2011, 10:609-616.
105. Motta M., Lachassinne E., Boffa M.C., Tincani A., Avcin T., De Carolis S., et al. European registry of infants born to mothers with antiphospholipid syndrome: preliminary results. Minerva Pediatr 2010, 62:25-27.
106. Zifman E., Litmanovitz I., Segal G., Regev R., Watemberg N. Marked hypotonia in an infant of a mother with Devic disease. J Child Neurol 2010, 25:746-747.
107. Behin A., Mayer M., Kassis-Makhoul B., Jugie M., Espil-Taris C., Ferrer X., et al. Severe neonatal myasthenia due to maternal anti-MuSK antibodies. Neuromuscul Disord 2008, 18:443-446.
108. O'Carroll P., Bertorini T.E., Jacob G., Mitchell C.W., Graff J. Transient neonatal myasthenia gravis in a baby born to a mother with new-onset anti-MuSK-mediated myasthenia gravis. J Clin Neuromuscul Dis 2009, 11:69-71.
109. Lewis K.A., Engle W., Hainline B.E., Johnson N., Corkins M., Eugster E.A. Neonatal Graves' disease associated with severe metabolic abnormalities. Pediatrics 2011, 128:e232-e236.
110. Aksentijevich I., Remmers E.F., Goldbach-Mansky R., Reiff A., Kastner D.L. Mutational analysis in neonatal-onset multisystem inflammatory disease. Arthritis Rheum 2006, 54. comment on the articles by Frenkel et al and Saito, et al, 2703-4; author reply 4-5.
111. Bensen J.T., Langefeld C.D., Hawkins G.A., Green L.E., Mychaleckyj J.C., Brewer C.S., et al. Nucleotide variation, haplotype structure, and association with end-stage renal disease of the human interleukin-1 gene cluster. Genomics 2003, 82:194-217.
112. Zhao S., Duncan M., Tomberg J., Davies C., Unemo M., Nicholas R.A. Genetics of chromosomally mediated intermediate resistance to ceftriaxone and cefixime in Neisseria gonorrhoeae. Antimicrob Agents Chemother 2009, 53:3744-3751.
113. Bachmann M., Chang S., Slor H., Kukulies J., Muller W.E. Shuttling of the autoantigen La between nucleus and cell surface after UV irradiation of human keratinocytes. Exp Cell Res 1990, 191:171-180.
114. Alshekaili J., Reynolds G., Cook M.C. De novo infantile primary antiphospholipid antibody syndrome. Lupus 2010, 19:1565-1568.
115. Matoba A.Y., O'Brien T.P., Wilhelmus K.R., Jones D.B. Infectious crystalline keratopathy due to Streptococcus pneumoniae. Possible association with serotype. Ophthalmology 1994, 101:1000-1004.
116. Nevo Y., Pestronk A. Neonatal perifascicular myopathy. Pediatr Neurol 1996, 15:150-152.
117. Carvalheiras G., Vita P., Marta S., Trovao R., Farinha F., Braga J., et al. Pregnancy and systemic lupus erythematosus: review of clinical features and outcome of 51 pregnancies at a single institution. Clin Rev Allergy Immunol 2010, 38:302-306.
118. Powell C., Chang C., Naguwa S.M., Cheema G., Gershwin M.E. Steroid induced osteonecrosis: an analysis of steroid dosing risk. Autoimmun Rev 2010, 9:721-743.
119. Saleeb S., Copel J., Friedman D., Buyon J.P. Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block: retrospective review of the research registry for neonatal lupus. Arthritis Rheum 1999, 42:2335-2345.
120. Carpenter R.J., Strasburger J.F., Garson A., Smith R.T., Deter R.L., Engelhardt H.T. Fetal ventricular pacing for hydrops secondary to complete atrioventricular block. J Am Coll Cardiol 1986, 8:1434-1436.
121. Friedman D.M., Llanos C., Izmirly P.M., Brock B., Byron J., Copel J., et al. Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: results of a multicenter, prospective, open-label clinical trial. Arthritis Rheum 2010, 62:1138-1146.
122. Andreoli L., Bazzani C., Taraborelli M., Reggia R., Lojacono A., Brucato A., et al. Pregnancy in autoimmune rheumatic diseases: the importance of counselling for old and new challenges. Autoimmun Rev 2010, 10:51-54.
123. Andreoli L., Fredi M., Nalli C., Reggia R., Lojacono A., Motta M., et al. Pregnancy implications for systemic lupus erythematosus and the antiphospholipid syndrome. J Autoimmun 2011.
124. Rubtsov A.V., Rubtsova K., Kappler J.W., Marrack P. Genetic and hormonal factors in female-biased autoimmunity. Autoimmun Rev 2010, 9:494-498.
125. Furukawa F., Lyons M.B., Lee L.A., Coulter S.N., Norris D.A. Estradiol enhances binding to cultured human keratinocytes of antibodies specific for SS-A/Ro and SS-B/La. Another possible mechanism for estradiol influence of lupus erythematosus. J Immunol 1988, 141:1480-1488.
126. Dailly E., Billaud E., Reliquet V., Breurec S., Perre P., Leautez S., et al. No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors. Eur J Clin Pharmacol 2004, 60:343-348.